Serotonin 2A receptor antagonists for treatment of schizophrenia

Bibliography

• McGrath J, Saha S, Chant D, Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008;30:67-76
   PubMed Web of Science ®Google Scholar
• Okasha T, Okasha A. Transcultural aspects of schizophrenia and old-age schizophrenia. In: Kasper S, Papadimitriou GM. editors. Schizophrenia. 2nd edition. Informa Healthcare; London: 2009
   Google Scholar
• Schultz SK, Andreasen NC. Schizophrenia. Lancet 1999;353:1425-30
   PubMed Web of Science ®Google Scholar
• Weickert TW, Goldberg TE, Gold JM, Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch Gen Psychiatry 2000;57:907-13
   PubMed Web of Science ®Google Scholar
• Van Os J, Rutten BP, Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr Bull 2008;34:1066-82
   PubMed Web of Science ®Google Scholar
• Wu EQ, Birnbaum HG, Shi L, The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-9
   PubMed Web of Science ®Google Scholar
• Mangalore R, Knapp M. Cost of schizophrenia in England. J Ment Health Policy Econ 2007;10:23-41
   PubMed Web of Science ®Google Scholar
• Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev 2009;CD006324
   Google Scholar
• Hulshoff Pol HE, Kahn RS. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull 2008;34:354-66
   PubMed Web of Science ®Google Scholar
• Seeman P, Lee T, Chau-Wong M, Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261:717-19
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Li Z, Kaneda Y, Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1159-72
   PubMed Web of Science ®Google Scholar
• Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 2001;158:360-9
   PubMed Web of Science ®Google Scholar
• Kim DH, Maneen MJ, Stahl SM. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics 2009;6:78-85
   PubMed Web of Science ®Google Scholar
• Gaddum JH, Hameed KA. Drugs which antagonize 5-hydroxytryptamine. Br J Pharmacol Chemother 1954;9:240-8
   PubMed Web of Science ®Google Scholar
• Geyer MA, Vollenweider FX. Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci 2008;29:445-53
   PubMed Web of Science ®Google Scholar
• Marona-Lewicka D, Thisted RA, Nichols DE. Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis. Psychopharmacology (Berl) 2005;180:427-35
   PubMed Web of Science ®Google Scholar
• Winter JC, Fiorella DJ, Helsley SE, Partial generalization of (-)DOM to fluvoxamine in the rat: implications for SSRI-induced mania and psychosis. Int J Neuropsychopharmacol 1999;2:165-72
   PubMed Web of Science ®Google Scholar
• Gray JA, Roth BL. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull 2001;56:441-51
   PubMed Web of Science ®Google Scholar
• Adams KH, Pinborg LH, Svarer C, A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables. Neuroimage 2004;21:1105-13
   PubMed Web of Science ®Google Scholar
• Arora RC, Meltzer HY. Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm Gen Sect 1991;85:19-29
   PubMed Web of Science ®Google Scholar
• Bennett JP Jr, Enna SJ, Bylund DB, Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 1979;36:927-34
   PubMed Web of Science ®Google Scholar
• Burnet PW, Eastwood SL, Harrison PJ. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 1996;15:442-55
   PubMed Web of Science ®Google Scholar
• Dean B, Hayes W. Decreased frontal cortical serotonin2A receptors in schizophrenia. Schizophr Res 1996;21:133-9
   PubMed Web of Science ®Google Scholar
• Dean B, Hayes W, Hill C, Decreased serotonin2A receptors in Brodmann's area 9 from schizophrenic subjects. A pathological or pharmacological phenomenon? Mol Chem Neuropathol 1998;34:133-45
   PubMedGoogle Scholar
• Dean B, Hussain T, Hayes W, Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. J Neurochem 1999;72:1593-9
   PubMed Web of Science ®Google Scholar
• Gurevich EV, Joyce JN. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol Psychiatry 1997;42:529-45
   PubMed Web of Science ®Google Scholar
• Laruelle M, Abi-Dargham A, Casanova MF, Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch Gen Psychiatry 1993;50:810-18
   PubMed Web of Science ®Google Scholar
• Matsumoto I, Inoue Y, Iwazaki T, 5-HT2A and muscarinic receptors in schizophrenia: a postmortem study. Neurosci Lett 2005;379:164-8
   PubMed Web of Science ®Google Scholar
• Mita T, Hanada S, Nishino N, Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry 1986;21:1407-14
   PubMed Web of Science ®Google Scholar
• Pralong D, Tomaskovic-Crook E, Opeskin K, Serotonin(2A) receptors are reduced in the planum temporale from subjects with schizophrenia. Schizophr Res 2000;44:35-45
   PubMed Web of Science ®Google Scholar
• Dean B, Hayes W, Opeskin K, Serotonin2 receptors and the serotonin transporter in the schizophrenic brain. Behav Brain Res 1996;73:169-75
   PubMed Web of Science ®Google Scholar
• Joyce JN, Shane A, Lexow N, Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 1993;8:315-36
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Rossor MN, Iversen LL. Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action. J Neural Transm Suppl 1983;18:273-7
   PubMedGoogle Scholar
• Whitaker PM, Crow TJ, Ferrier IN. Tritiated LSD binding in frontal cortex in schizophrenia. Arch Gen Psychiatry 1981;38:278-80
   PubMed Web of Science ®Google Scholar
• Gonzalez-Maeso J, Ang RL, Yuen T, Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008;452:93-7
   PubMed Web of Science ®Google Scholar
• Hernandez I, Sokolov BP. Abnormalities in 5-HT2A receptor mRNA expression in frontal cortex of chronic elderly schizophrenics with varying histories of neuroleptic treatment. J Neurosci Res 2000;59:218-25
   PubMed Web of Science ®Google Scholar
• Dean B. The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice. J Neurochem 2003;85:1-13
   PubMed Web of Science ®Google Scholar
• Lewis R, Kapur S, Jones C, Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects. Am J Psychiatry 1999;156:72-8
   PubMed Web of Science ®Google Scholar
• Okubo Y, Suhara T, Suzuki K, Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography. Life Sci 2000;66:2455-64
   PubMed Web of Science ®Google Scholar
• Trichard C, Paillere-Martinot ML, Attar-Levy D, No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophr Res 1998;31:13-17
   PubMed Web of Science ®Google Scholar
• Ngan ET, Yatham LN, Ruth TJ, Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: A PET study using [(18)F]setoperone. Am J Psychiatry 2000;157:1016-18
   PubMed Web of Science ®Google Scholar
• Rasmussen H, Erritzoe D, Andersen R, Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia. Arch Gen Psychiatry 2010;67:9-16
   PubMed Web of Science ®Google Scholar
• Erritzoe D, Rasmussen H, Kristiansen KT, Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients. Neuropsychopharmacology 2008;33:2435-41
   PubMed Web of Science ®Google Scholar
• Hurlemann R, Boy C, Meyer PT, Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia. Anat Embryol (Berl) 2005;210:519-23
   PubMedGoogle Scholar
• Cardno AG, Marshall EJ, Coid B, Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch Gen Psychiatry 1999;56:162-8
   PubMed Web of Science ®Google Scholar
• Pinborg LH, Arfan H, Haugbol S, The 5-HT2A receptor binding pattern in the human brain is strongly genetically determined. Neuroimage 2008;40:1175-80
   PubMed Web of Science ®Google Scholar
• Shinkai T, Ohmori O, Kojima H, Negative association between T102C polymorphism of the 5-HT2a receptor gene and schizophrenia in Japan. Hum Hered 1998;48:212-15
   PubMed Web of Science ®Google Scholar
• Abdolmaleky HM, Faraone SV, Glatt SJ, Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr Res 2004;67:53-62
   PubMed Web of Science ®Google Scholar
• Quednow BB, Kuhn KU, Mossner R, Sensorimotor gating of schizophrenia patients is influenced by 5-HT2A receptor polymorphisms. Biol Psychiatry 2008;64:434-7
   PubMed Web of Science ®Google Scholar
• Quednow BB, Schmechtig A, Ettinger U, Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase, but not on neuregulin-1 Arg38Gln genotype: a replication study. Biol Psychiatry 2009;66:614-20
   PubMed Web of Science ®Google Scholar
• Joober R, Benkelfat C, Brisebois K, T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability. J Psychiatry Neurosci 1999;24:141-6
   PubMed Web of Science ®Google Scholar
• Arranz MJ, Munro J, Owen MJ, Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry 1998;3:61-6
   PubMed Web of Science ®Google Scholar
• Kane J, Honigfeld G, Singer J, Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Arvanitis L, Bauer D, Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 2004;161:975-84
   PubMed Web of Science ®Google Scholar
• Lohr JB, Braff DL. The value of referring to recently introduced antipsychotics as "second generation". Am J Psychiatry 2003;160:1371-2
   PubMed Web of Science ®Google Scholar
• Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004;3:353-9
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989;251:238-46
   PubMed Web of Science ®Google Scholar
• Hertel P, Didriksen M, Pouzet B, Lu 35-138 ((+)-(S)-3-{1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-3,6-dihydro-2H-pyridi n-4-yl}-6-chloro-1H-indole), a dopamine D4 receptor antagonist and serotonin reuptake inhibitor: characterisation of its in vitro profile and pre-clinical antipsychotic potential. Eur J Pharmacol 2007;573:148-60
   PubMed Web of Science ®Google Scholar
• Auclair A, Blanc G, Glowinski J, Role of serotonin 2A receptors in the D-amphetamine-induced release of dopamine: comparison with previous data on alpha1b-adrenergic receptors. J Neurochem 2004;91:318-26
   PubMed Web of Science ®Google Scholar
• Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 2001;158:360-9
   PubMed Web of Science ®Google Scholar
• Wolkin A, Barouche F, Wolf AP, Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989;146:905-8
   PubMed Web of Science ®Google Scholar
• Nyberg S, Eriksson B, Oxenstierna G, Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 1999;156:869-75
   PubMed Web of Science ®Google Scholar
• Grunder G, Fellows C, Janouschek H, Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry 2008;165:988-95
   PubMed Web of Science ®Google Scholar
• Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des 2010;16:488-501
   PubMed Web of Science ®Google Scholar
• Farde L, Nyberg S, Oxenstierna G, Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 1995;15:19S-23S
   PubMed Web of Science ®Google Scholar
• Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153:466-76
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156:286-93
   PubMed Web of Science ®Google Scholar
• Mamo D, Kapur S, Shammi CM, A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004;161:818-25
   PubMed Web of Science ®Google Scholar
• Gefvert O, Bergstrom M, Langstrom B, Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl) 1998;135:119-26
   PubMed Web of Science ®Google Scholar
• Mamo D, Graff A, Mizrahi R, Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 2007;164:1411-17
   PubMed Web of Science ®Google Scholar
• Rasmussen H, Ebdrup BH, Erritzoe D, Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine. Psychopharmacology (Berl) 2011;213:583-92
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41
   PubMed Web of Science ®Google Scholar
• Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 2007;113:296-320
   PubMed Web of Science ®Google Scholar
• Glenthoj BY, Hemmingsen R. Transmitter dysfunction during the process of schizophrenia. Acta Psychiatr Scand Suppl 1999;395:105-12
   PubMedGoogle Scholar
• Liu R, Jolas T, Aghajanian G. Serotonin 5-HT(2) receptors activate local GABA inhibitory inputs to serotonergic neurons of the dorsal raphe nucleus. Brain Res 2000;873:34-45
   PubMed Web of Science ®Google Scholar
• Lewis DA, Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nat Med 2006;12:1016-22
   PubMed Web of Science ®Google Scholar
• Vazquez-Borsetti P, Cortes R, Artigas F. Pyramidal neurons in rat prefrontal cortex projecting to ventral tegmental area and dorsal raphe nucleus express 5-HT2A receptors. Cereb Cortex 2009;19:1678-86
   PubMed Web of Science ®Google Scholar
• Lukasiewicz S, Polit A, Kedracka-Krok S, Hetero-dimerization of serotonin 5-HT(2A) and dopamine D(2) receptors. Biochim Biophys Acta 2010;1803:1347-58
   PubMed Web of Science ®Google Scholar
• Meltzer H. Schizophrenia Forum. 2010. Available from: http://www.schizophreniaforum.org/pap/readmore.asp?commentID=%7BD8B800EA-14DC-49AA-9F99-662CCC039153%7D/ [Accessed December 2010]
   Google Scholar
• Stone JM. Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia. Curr Pharm Des 2009;15:2594-602
   PubMed Web of Science ®Google Scholar
• Patil ST, Zhang L, Martenyi F, Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007;13:1102-7
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Zhang L, Millen BA, A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia. J Clin Psychopharmacol 2011;31:349-55
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. Clinical trials. 2011 Available from: http://clinicaltrials.gov/ct2/show/NCT01052103/ [Accessed May 2011]
   Google Scholar
• Uslaner JM, Smith SM, Huszar SL, Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants. Psychopharmacology (Berl) 2009;206:641-51
   PubMed Web of Science ®Google Scholar
• Ebdrup BH, Skimminge A, Rasmussen H, Progressive striatal and hippocampal volume loss in initially antipsychotic-naive, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms. Int J Neuropsychopharmacol 2011;14:69-82
   PubMed Web of Science ®Google Scholar
• Navari S, Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol Med 2009;39:1763-77
   PubMed Web of Science ®Google Scholar
• De Paulis T. M-100907 (Aventis). Curr Opin Investig Drugs 2001;2:123-32
   PubMedGoogle Scholar
• Talvik-Lotfi M, Nyberg S, Nordstrom AL, High 5HT2A receptor occupancy in M100907-treated schizophrenic patients. Psychopharmacology (Berl) 2000;148:400-3
   PubMed Web of Science ®Google Scholar
• Benekareddy M, Goodfellow NM, Lambe EK, Enhanced function of prefrontal serotonin 5-HT(2) receptors in a rat model of psychiatric vulnerability. J Neurosci 2010;30:12138-50
   PubMed Web of Science ®Google Scholar
• Meyer PT, Bhagwagar Z, Cowen PJ, Simplified quantification of 5-HT2A receptors in the human brain with [11C]MDL 100,907 PET and non-invasive kinetic analyses. Neuroimage 2010;50:984-93
   PubMed Web of Science ®Google Scholar
• Rinaldi-Carmona M, Congy C, Santucci V, Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist. J Pharmacol Exp Ther 1992;262:759-68
   PubMed Web of Science ®Google Scholar
• Bonaccorso S, Meltzer HY, Li Z, SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology 2002;27:430-41
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment–pharmacological mechanisms. Pharmacol Ther 2010;125:169-79
   PubMed Web of Science ®Google Scholar
• Press release. 2011. Available from: http://www.farmavita net/content/view/1312/84/ [Accessed January 2011]
   Google Scholar
• Abbas A, Roth BL. Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin Pharmacother 2008;9:3251-9
   PubMed Web of Science ®Google Scholar
• Press release. Cyrenaic Pharmaceuticals. 2011. Available from: www.cyrenaicpharma.com
   Google Scholar
• Vanover KE, Weiner DM, Makhay M, Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phen ylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 2006;317:910-18
   PubMed Web of Science ®Google Scholar
• Press release. Acadia pharmaceuticals. 2004. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=125180&p=irol-newsArticle&ID=614559&highlight=/ [Accessed January 2011]
   Google Scholar
• Press release. Acadia pharmaceuticals. 2005. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=125180&p=irol-newsArticle&ID=791782&highlight/ [Accessed January 2011]
   Google Scholar
• Press release. Acadia pharmaceuticals. 2007. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=125180&p=irol-newsArticle&ID=974982&highlight=/ [Accessed January 2011]
   Google Scholar
• Meltzer HY, Mills R, Revell S, Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology 2010;35:881-92
   PubMed Web of Science ®Google Scholar
• Reimold M, Solbach C, Noda S, Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl) 2007;190:241-9
   PubMed Web of Science ®Google Scholar
• Nordstrom AL, Mansson M, Jovanovic H, PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain. Int J Neuropsychopharmacol 2008;11:163-71
   PubMed Web of Science ®Google Scholar
• Mehler-Wex C, Riederer P, Gerlach M. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res 2006;10:167-79
   PubMed Web of Science ®Google Scholar
• Press release. Cyrenaic Pharmaceuticals. 2010. Available from: http://www.cyrenaicpharma.com/media/cyrenaic-press_release-schizophrenia.pdf/ [Accessed January 2011]
   Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Landolt HP, Wehrle R. Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood? Eur J Neurosci 2009;29:1795-809
   PubMed Web of Science ®Google Scholar
• Rosenberg R, Seiden DJ, Hull SG, APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia. Sleep 2008;31:1663-71
   PubMed Web of Science ®Google Scholar
• Press release. Arena Pharmaceuticals. 2008. Available from: http://www.drugdevelopment-technology.com/projects/arena/ [Accessed January 2011]
   Google Scholar
• Kehne JH, Baron BM, Carr AA, Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 1996;277:968-81
   PubMed Web of Science ®Google Scholar
• Rinaldi-Carmona M, Congy C, Santucci V, Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist. J Pharmacol Exp Ther 1992;262:759-68
   PubMed Web of Science ®Google Scholar